1. Introduction {#s0005}
===============

Uncontrolled hypertension is the most common risk factor for cardiovascular disease (CVD) and is responsible for a large number of deaths and disabilities within the US ([@bb0065]; [@bb0080]). The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults has changed the systolic/diastolic blood pressure (SBP/DBP) thresholds to define hypertension ([@bb0165]). Previous guidelines such as the Seventh Joint National Committee Guideline (JNC 7) recommends the SBP/DBP thresholds as 140/90 mmHg; however, the new guideline recommends the cutoffs as 130/80 mmHg, 10 mmHg lower than the SBP/DBP thresholds of the previous guidelines ([@bb0035]; [@bb0045]; [@bb0165]). Furthermore, the term 'prehypertension' has been replaced with a new term 'elevated BP' which recommends the SBP cutoff as 120--129 mmHg while the person has a normal DBP (i.e., \<80 mmHg) ([@bb0165]). The 2017 ACC/AHA guideline has also changed the recommendations about treatment initiations and treatment goals. More than 45% of US adults (i.e., aged ≥20 years) could be hypertensive as per the new guideline ([@bb0115]). Other studies also support this finding ([@bb0050]; [@bb0105]). Although this guideline has classified a substantial proportion of adults as hypertensive who would have been known as prehypertensive per the previous guidelines, it provides a greater opportunity to take prevention and treatment measures in the early stages of hypertension ([@bb0115]; [@bb0165]). Additionally, adoption of the new guideline could substantially reduce the cardiovascular events resulting from hypertension ([@bb0020]; [@bb0165]; [@bb0170]).

Studies from the US have consistently reported that the prevalence and likelihoods of hypertension differ by race. According to Dorans et al., the age-adjusted prevalence of hypertension was about 8.5% higher among non-Hispanic blacks compared to non-Hispanic whites in 2015--16. In addition to non-Hispanic blacks, the age-adjusted prevalence of hypertension was higher among Mexican-Americans or other races ([@bb0050]). The proportion of people who would require pharmacotherapy for hypertension or who have unmet treatment goals could also be substantially higher among non-Hispanic blacks compared to other races ([@bb0115]). Moreover, studies reported that Mexican-Americans could remain untreated despite having indications for treatment ([@bb0075]; [@bb0130]). Differences in awareness, lifestyle, and socioeconomic characteristics could be responsible for these disparities ([@bb0075]; [@bb0165]). Considering the clinical and public health importance of hypertension, estimates of prevalence, control, or treatment of hypertension according to characteristics such as age, gender, kidney disease, body weight, or cholesterol levels among racial groups in the US are also essential to investigate. While earlier studies found that the new guideline could change the estimates of overall hypertension burden per race in the US, how these estimates of hypertension could differ according to characteristics among different races have not been estimated yet. Furthermore, there have been limited recent studies that investigate racial disparities related to prevalence, control, and treatment of hypertension together. To understand the racial disparities related to hypertension burden, new studies are needed that quantify the prevalence, control, and treatment status of hypertensive individuals according to race with recent data per the latest guideline. To address these gaps in the literature, this study obtained the aforementioned estimates by race among US adults.

2. Methods {#s0010}
==========

2.1. Data source {#s0015}
----------------

This study used the National Health and Nutrition Examination Survey (NHANES) data. The continuous NHANES is a cross-sectional survey. The primary aim of this biennial survey is to obtain nationally representative samples of the non-institutionalized US population. Details of the survey are available elsewhere ([@bb0175]). This analysis was limited to 2011--16 survey years to report the most recent estimates. These publicly available datasets were downloaded and merged according to unique identification numbers. The Ethics Review Board of the National Center for Health Statistics approved the survey protocols ([@bb0120]).

2.2. Study variables {#s9015}
--------------------

Using factory-calibrated 'Baumanometer® mercury true gravity wall model sphygmomanometers', trained physicians measured the BP in mobile examination centers. The BP was recorded for four times in the seated position after resting for 5 min. Appropriate cuff sizes were used ([@bb0030]; [@bb0175]). In this study, the mean of the first 3 BP measurements was used to calculate BP levels. If an individual had an SBP of 120--129 mmHg with a normal DBP (i.e., \<80 mmHg), then the BP level was classified as elevated BP. To classify an individual as stage 1 and stage 2 hypertensive, the following SBP/DBP thresholds were used, respectively (in mmHg), 130--139/80--89 and ≥140/90. Hypertension includes both stage 1 and stage 2 hypertension. Individuals who reported that they were currently taking BP lowering drugs were categorized as hypertensive regardless of BP levels ([Supplemental Table 1](#ec0005){ref-type="supplementary-material"}) ([@bb0115]; [@bb0165]).

Participants reported their race/ethnicity, and were grouped as non-Hispanic whites, non-Hispanic blacks, Mexican-Americans, and other races/ethnicities. Due to a lower proportion of respondents from races/ethnicities other than the first 3 races, all other races (i.e., non-Hispanic Asians, other Hispanics, and other races including multi-races) were grouped as other races/ethnicities. Participants also reported their age (in years) and gender. Age was stratified into 20--44, 45--54, 55--64, and ≥65 years ([@bb0115]). Borderline elevated and high cholesterol levels were defined as 200--239 and ≥240 mg/dl cholesterol levels, respectively. If the high-density lipoprotein (HDL) was \<40 mg/dl for men and \<50 mg/dl for women, it was categorized as low ([@bb0125]). Self-reports for diagnosis of prediabetes and diabetes were obtained. The chronic kidney disease Epidemiology (CKD-EPI) equation was used to estimate the glomerular filtration rate (GFR). A person was categorized as CKD if the albumin-creatinine ratio was ≥30 mg/g or the GFR was \<60 ml/min per 1.73 m^2^ ([@bb0110]). 'Weight in kilograms' was divided by 'height in meters squared' to obtain body mass index (BMI). The BMI cutoffs to define under-/normal weight, overweight, and obesity were \<25, 25--29.9, and ≥30 kg/m^2^, respectively. NHANES also reports family income to poverty ratio. This is the ratio of family\'s income and poverty threshold based on the number of family members; a higher ratio indicates a higher income ([@bb0125]; [@bb0150]). This ratio was stratified as '\<2' and '≥2'. Participants were also asked about the number of health care visits they have done over the past year; which was categorized as 0, 1--3, and ≥4 ([@bb0125]). CVD event was defined if a person had a history of myocardial infarction, coronary heart disease, stroke, or heart failure. Among people without CVD event, 10-year predicted CVD risk was obtained with pooled cohort risk equations ([@bb7000]). Previous CVD event or ≥10% 10-year CVD risk was considered as high CVD risk ([@bb0115]; [@bb0165]).

Persons with stage 2 hypertension, stage 1 hypertension with diabetes, CKD, or high CVD risk, and SBP ≥130 mmHg with ≥65 years of age were considered as treatment-eligible for hypertension ([Supplemental Table 1](#ec0005){ref-type="supplementary-material"}). Among individuals who reported that they were currently taking antihypertensive drugs, the following individuals were considered as not meeting treatment goals: if the SBP/DBP was ≥130/80 mmHg among age groups \<65 years and if the SBP was ≥130 mmHg among age groups ≥65 years ([Supplemental Table 1](#ec0005){ref-type="supplementary-material"}) ([@bb0115]; [@bb0165]).

2.3. Statistical analysis {#s0020}
-------------------------

The background characteristics of the hypertensive and overall study participants were reported according to their race. Mean and standard error (SE) were used to report continuous variables while categorical variables were reported with weighted percentages and unweighted numbers. During comparison, continuous variables were tested with *t*-tests and categorical variables were tested with chi-square tests. Then, the age-adjusted proportion (with 95% confidence interval \[CI\]) of individuals with hypertension, people with treatment-eligibility for hypertension, people who were not taking antihypertensive drugs despite being treatment-eligible, and people with unmet treatment goals among treated were reported according to race as well as the overall population. The age distributions from the 2015 population census were used to obtain age-adjusted estimates ([@bb0155]). The analysis also accounted for multistage cluster sampling design of the NHANES to obtain all the estimates ([@bb0090]); using the mobile examination center\'s weights, all the weighted estimates were reported. Overall, due to a lower proportion of missing data (\<10%), variables with missing data were neither dropped nor imputed (i.e., available case analysis) ([@bb0095]). Stata 14.0 was used to analyze data. The 'svy' command in Stata allows to adjust for the multistage cluster-sampling design ([@bb0145]).

3. Results {#s0025}
==========

The analysis included 16,103 respondents aged ≥20 years ([Table 1](#t0005){ref-type="table"}). The mean age of the participants was 47.6 years (SE: 0.4). About 51.8% of the respondents were females. Most of the characteristics differed according to race (*p* \< 0.05). The proportion of hypertensive people with a high cholesterol level was higher among non-Hispanic whites while Mexican-Americans had a higher proportion of hypertensive people with young age, diabetes, obesity, and low family income to poverty ratio. Overall, 24.8% people had high CVD risk.Table 1Background characteristics of the hypertensive study participants by race, NHANES 2011--16[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}.Table 1CharacteristicsOverall study population\
(*N* = 16,103)Hypertensive participants by raceNon-Hispanic White (*n* = 3132/6066)Non-Hispanic Blacks, (*n* = 2253/3665)Mexican-Americans, (*n* = 981/2164)Other races/ethnicities [c](#tf0015){ref-type="table-fn"}, (*n* = 1885/4208)All races, (*n* = 8251/16,103)*p*-Value[d](#tf0020){ref-type="table-fn"}**SBP**, mean (SE), mmHg122.4 (0.3)133.0 (0.5)136.8 (0.6)134.8 (0.8)134.8 (0.6)133.9 (0.4)\<0.01**DBP**, mean (SE), mmHg70.7 (0.2)74.4 (0.4)76.1 (0.6)76.1 (0.7)76.2 (0.6)74.9 (0.3)\<0.01  **Age (in years)**Mean (SE)47.6 (0.4)57.8 (0.4)52.8 (0.6)49.9 (1.1)53.6 (0.7)56.1 (0.3)\<0.00120--4444.7 (6797)19.8 (587)29.1 (493)39.1 (229)29.5 (414)23.6 (1723)\<0.00145--5418.7 (2720)18.9 (487)23.8 (445)23.3 (178)20.7 (354)20.1 (1464)55--6417.3 (2798)25.5 (593)24.9 (634)19.2 (271)21.7 (480)24.5 (1978)≥6519.2 (3788)35.8 (1465)22.2 (681)18.4 (303)28.0 (637)31.8 (3086)  **Gender**Male48.2 (7811)51.0 (1616)46.2 (1133)56.5 (516)52.6 (963)50.9 (4228)\<0.001Female51.8 (8292)49.0 (1516)53.8 (1120)43.5 (465)47.4 (922)49.1 (4023)  **Cholesterol level (in mg/dl)**Normal (\<200)45.9 (7039)29.7 (905)43.5 (832)37.8 (312)34.8 (568)32.6 (2617)\<0.001Borderline (200--239)24.0 (3504)23.0 (631)19.7 (398)26.8 (229)23.8 (423)22.9 (1681)High (≥240)30.0 (4734)47.4 (1470)36.8 (848)35.5 (391)41.4 (780)44.5 (3489  **High-density lipoprotein cholesterol (in mg/dl)**Normal70.5 (10357)67.9 (1924)72.1 (1467)60.9 (565)62.8 (1096)67.4 (5052)\<0.001Low (\<40 for men & \<50 for women)29.5 (4671)32.1 (1003)27.9 (526)39.1 (356)37.2 (624)32.6 (2509)  **Chronic kidney disease**No85.1 (12981)76.4 (2118)75.5 (1583)76.9 (706)78.2 (1408)76.5 (5815)0.47Yes14.9 (2814)23.6 (928)24.5 (586)23.1 (254)21.8 (416)23.5 (2184)  **Diabetes mellitus status**No83.4 (12515)75.7 (2229)71.1 (1466)68.7 (596)71.2 (1270)74.0 (5561)\<0.001Prediabetes6.1 (950)8.2 (238)6.8 (144)7.1 (70)9.4 (160)8.1 (612)Diabetes10.5 (2221)16.1 (550)22.1 (548)24.2 (284)19.4 (387)17.9 (1769)  **Body mass index (in kg/m2)**Normal/underweight (\<25)29.5 (4695)19.5 (642)18.4 (421)10.4 (108)28.5 (552)19.8 (1723)\<0.001Overweight (25--29.9)32.8 (5038)34.1 (1000)25.9 (590)31.5 (311)31.2 (615)32.5 (2516)Obese (≥30)37.8 (6013)46.4 (1368)55.7 (1164)58.1 (533)40.2 (649)47.7 (3714)  **Number of health care visits within the past year**015.3 (2600)9.3 (276)12.1 (246)21.6 (168)16.7 (282)11.4 (972)\<0.0011--364.8 (10264)63.7 (1904)67.5 (1528)61.4 (608)62.7 (1194)63.9 (5234)≥419.9 (3223)27.0 (948)20.4 (478)17.0 (203)20.6 (407)24.7 (2036)  **Family income-to-poverty ratio**\<236.7 (7305)29.1 (1331)53.7 (1083)64.6 (566)46.2 (821)36.6 (3801)0.07≥263.3 (7383)70.9 (1609)46.3 (925)35.4 (291)53.8 (836)63.4 (3661)  **10-yr CVD risk categories**Low75.2 (9652)53.7 (1159)55.8 (865)70.1 (460)60.4 (845)55.9 (3329)\<0.001High24.8 (4322)46.3 (1520)44.2 (988)29.9 (374)39.3 (694)44.1 (3576)[^1][^2][^3][^4][^5]

[Table 2](#t0010){ref-type="table"} shows the age-adjusted prevalence of hypertension according to race and the prevalence among the overall population. The prevalence of hypertension was 45.7% (95% CI: 44.1%--47.3%) among non-Hispanic whites, 59.0% (95% CI: 57.4%--60.6%) among non-Hispanic blacks, 46.1% (95% CI: 43.8%--48.3%) among Mexican-Americans, 45.2% (95% CI: 43.3%--47.2%) among other races/ethnicities, and 46.9% (95% CI: 45.8%--48.1%) among overall population. In all race categories, males had a higher prevalence of hypertension compared to females. The characteristics (e.g., overweight/obesity, high cholesterol, CKD, or the number of health care visits) that had higher prevalence in one racial category also had higher prevalence in other racial categories. Regardless of characteristics, non-Hispanic blacks had the highest prevalence among all races. For some of the characteristics like high CVD risk, diabetes mellitus, CKD, and high cholesterol level, about three-fourths of non-Hispanic blacks had hypertension. [Figure 1](#f0005){ref-type="fig"} shows the age-adjusted prevalence of blood pressure stages by race. The overall prevalence of stage 1 hypertension was similar across races; however, the prevalence of stage 2 hypertension and the proportion of people on antihypertensive medication was highest among non-Hispanic blacks.Table 2Age-adjusted prevalence (with 95% confidence interval) of hypertension according to race, NHANES 2011--16[a](#tf0025){ref-type="table-fn"}.Table 2CharacteristicsNon-Hispanic WhitesNon-Hispanic BlacksMexican-AmericansOther races/ethnicities[b](#tf0030){ref-type="table-fn"}In all races**Age (in years)**20--4424.6 (22.3--27.0)32.3 (29.5--35.2)22.3 (19.5--25.4)21.2 (18.6--24.0)24.7 (23.0--26.4)45--5447.8 (43.3--52.4)68.3 (63.9--72.4)49.0 (43.2--54.7)46.4 (42.6--50.3)50.1 (47.3--53.0)55--6463.8 (60.4--67.1)83.8 (80.5--86.7)66.1 (60.1--71.5)65.6 (61.0--70.0)66.3 (63.8--68.8)≥6575.8 (73.1--78.4)89.7 (87.3--91.8)79.8 (73.1--85.2)80.9 (77.3--84.1)77.7 (75.3--79.8)  **Sex**Male49.3 (46.9--51.7)60.9 (58.9--62.9)48.2 (45.3--51.2)49.1 (46.6--51.7)50.2 (48.4--51.9)Female42.0 (40.1--43.9)57.4 (55.2--59.7)43.6 (41.3--46.0)41.6 (39.4--43.8)43.7 (42.3--45.1)  **Cholesterol level (in mg/dl)**Normal (\<200)40.3 (37.9--42.8)56.0 (53.9--58.2)39.4 (37.0--42.0)41.3 (38.2--44.5)42.2 (40.4--44.1)Borderline (200--239)44.4 (41.4--47.4)55.6 (52.1--59.1)45.7 (40.0--51.6)44.9 (41.2--48.6)45.2 (42.9--47.5)High (≥240)57.9 (54.3--61.5)73.5 (68.3--78.1)59.1 (53.4--64.7)56.2 (52.1--60.3)59.2 (56.3--61.9)  **High-density lipoprotein cholesterol (in mg/dl)**Normal42.0 (40.1--43.9)56.6 (54.6--58.5)44.8 (42.2--47.4)43.0 (41.0--45.1)43.8 (42.4--45.2)Low (\<40 for men & \<50 for women)53.8 (51.5--56.1)64.9 (62.0--67.8)47.1 (43.2--51.0)49.4 (46.7--52.1)53.2 (51.5--54.9)  **Chronic kidney disease**No43.7 (42.0--45.4)56.4 (54.6--58.3)42.8 (40.9--44.8)43.0 (40.9--45.1)44.6 (43.3--45.9)Yes58.7 (53.8--63.4)74.1 (69.2--78.5)65.5 (60.4--70.3)61.5 (56.4--66.3)62.2 (58.9--65.4)  **Diabetes mellitus status**No42.8 (40.9--44.6)56.3 (54.1--58.4)42.5 (40.0--44.9)42.6 (40.4--44.8)43.9 (42.6--45.3)Prediabetes54.1 (46.8--61.1)64.8 (53.2--74.9)52.0 (41.7--62.1)57.2 (51.8--62.4)55.8 (50.8--60.6)Diabetes73.9 (67.8--79.2)76.9 (68.8--83.4)65.8 (58.6--72.4)57.5 (49.8--64.8)70.2 (66.3--73.8)  **Body mass index (in kg/m^2^)**Normal/underweight (\<25)32.4 (30.0--34.8)49.7 (46.8--52.6)32.8 (28.0--38.1)36.8 (33.7--40.0)34.6 (32.8--36.5)Overweight (25--29.9)44.7 (42.4--46.9)53.9 (51.7--56.1)42.3 (39.0--45.6)44.0 (41.8--46.1)44.9 (43.3--46.5)Obese (≥30)57.9 (55.6--60.0)67.3 (64.9--69.6)53.1 (50.0--56.1)57.1 (53.4--60.7)58.2 (56.6--59.7)  **Family income to poverty ratio**\<247.8 (45.3--50.4)60.4 (58.2--62.7)47.2 (44.7--49.7)46.1 (43.9--48.3)49.5 (48.1--50.9)≥245.2 (43.2--47.2)57.7 (55.3--60.0)44.5 (41.1--47.9)43.9 (41.0--47.0)45.8 (44.3--47.3)  **Number of health care visits within the past year**042.6 (37.4--47.9)58.5 (53.8--63.1).40.8 (36.4--45.3)40.4 (35.3--45.8)43.2 (39.8--46.7)1--344.4 (42.7--46.2)58.1 (56.5--59.7)46.7 (44.0--49.5)44.5 (42.0--47.0)46.0 (44.6--47.4)≥450.4 (46.9--53.9)64.1 (60.1--67.9)49.8 (44.2--55.4)48.9 (44.5--53.3)51.4 (48.7--54.1)  **10-yr CVD risk categories**Low36.1 (33.9--38.3)51.6 (48.3--54.8)39.7 (36.9--42.6)36.0 (33.5--38.7)37.3 (35.6--39.0)High63.0 (56.3--69.2)85.7 (78.9--90.6)61.5 (49.3--72.5)68.6 (59.2--76.7)67.4 (62.7--71.8)**Overall**45.7 (44.1--47.3)59.0 (57.4--60.6)46.1 (43.8--48.3)45.2 (43.3--47.2)46.9 (45.8--48.1)[^6][^7][^8]Fig. 1Age-adjusted prevalence of blood pressure stages according to race, National Health and Nutrition Examination Survey 2011--16.Fig. 1

The proportion of age-adjusted treatment-eligible individuals was 35.7% (95% CI: 34.3%--37.2%), 49.3% (95% CI: 47.7%--50.8%), 36.6% (95% CI: 34.1%--39.2%), 36.0% (95% CI: 34.3%--37.8%), and 37.2% (95% CI: 36.0%--38.3%) among non-Hispanic whites, non-Hispanic blacks, Mexican-Americans, other races/ethnicities, and the overall population, respectively ([Table 3](#t0015){ref-type="table"}). Similar to estimates from [Table 2](#t0010){ref-type="table"}, characteristics that had a higher prevalence of hypertension also had increased indication for treatment, and non-Hispanic blacks were more likely to be eligible compared to other races as per most characteristics.Table 3Age-adjusted proportion (with 95% confidence interval) of individuals require antihypertensive medication with characteristics stratified by race, NHANES 2011--16[a](#tf0035){ref-type="table-fn"}.Table 3CharacteristicsNon-Hispanic WhitesNon-Hispanic BlacksMexican-AmericansOther races/ethnicities[b](#tf0040){ref-type="table-fn"}In all races**Age (in years)**20-4412.2 (10.5-14.0)19.3 (17.1-21.6)11.2 (9.3-13.5)10.1 (8.6-11.8)12.6 (11.4-13.9)45-5432.4 (28.6-36.4)53.4 (48.9-57.9)32.4 (26.3-39.3)33.0 (29.5-36.8)34.9 (32.3-37.7)55-6455.0 (51.0-59.0)77.0 (73.0-80.5)57.1 (50.6-63.3)55.4 (50.7-60.0)57.6 (54.6-60.5)≥6575.1 (72.4-77.6)89.2 (86.5-91.5)79.8 (73.1-85.2)80.6 (76.8-83.8)77.0 (74.7-79.2)  **Sex**Male37.7 (35.7-39.8)48.9 (46.9-50.8)36.0 (32.6-39.5)37.3 (35.1-39.5)38.4 (36.9-40.1)Female33.6 (32.0-35.3)49.5 (47.4-51.6)37.1 (34.6-39.7)34.9 (32.8-37.1)35.8 (34.5-37.2)  **Cholesterol level (in mg/dl)**Normal (\<200)31.1 (28.9-33.5)45.7 (43.0-48.3)30.7 (28.0-33.6)33.2 (30.5-36.0)33.2 (31.5-35.0)Borderline (200-239)32.7 (29.8-35.7)43.9 (41.3-46.5)35.0 (28.9-41.5)33.5 (30.5-36.7)33.6 (31.4-35.8)High (≥240)48.5 (44.8-52.2)64.3 (59.3-69.0)47.3 (41.7-52.9)45.9 (41.7-50.2)49.3 (46.2-52.3)  **High-density lipoprotein cholesterol (in mg/dl)**Normal32.6 (30.7-34.6)46.5 (44.5-48.6)35.3 (32.6-38.1)33.4 (31.6-35.3)34.3 (32.8-35.8)Low (\<40 for men & \<50 for women)43.0 (40.4-45.6)55.8 (52.6-59.0)38.8 (35.6-42.1)41.4 (38.4-44.5)43.5 (41.6-45.4)  **Chronic kidney disease**No32.7 (31.3-34.2)45.2 (43.3-47.0)32.2 (30.0-34.5)32.8 (31.0-34.8)33.8 (32.6-35.0)Yes58.7 (53.8-63.4)74.1 (69.2-78.5)65.5 (60.4-70.3)61.5 (56.4-66.3)62.2 (58.9-65.4)  **Diabetes mellitus status**No31.7 (30.1-33.3)45.0 (43.1-47.0)31.6 (28.9-34.3)32.4 (30.3-34.6)33.0 (31.7-34.2)Prediabetes54.1 (46.8-61.1)64.8 (53.2-74.9)52.0 (41.7-62.1)57.2 (51.8-62.4)55.8 (50.8-60.6)Diabetes68.0 (60.7-74.5)72.5 (64.7-79.0)55.8 (49.2-62.3)51.5 (43.7-59.2)63.9 (59.5-68.0)  **Body mass index (in kg/m**^**2**^**)**Normal/underweight (\<25)24.5 (22.5-26.7)40.3 (37.7-43.0)25.4 (20.9-30.6)28.7 (26.1-31.5)26.6 (25.0-28.2)Overweight (25-29.9)33.4 (31.9-35.0)43.4 (41.0-45.8)32.8 (29.2-36.6)35.0 (32.7-37.4)34.3 (33.1-35.6)Obese (≥30)46.2 (44.2-48.1)57.5 (55.2-59.7)42.9 (39.7-46.1)45.9 (42.7-49.2)47.1 (45.6-48.7)  **Family income to poverty ratio**\<239.6 (37.5-41.8)51.1 (49.1-53.0)37.0 (34.0-40.0)37.8 (35.4-40.2)40.8 (39.4-42.2)≥234.4 (32.6-36.2)47.8 (45.6-50.0)35.7 (33.0-38.6)34.2 (31.6-36.8)35.3 (33.9-36.8)  **Number of health care visits within the past year**029.1 (25.2-33.4)42.3 (39.1-45.8)30.6 (25.7-35.9)27.7 (22.5-33.6)30.1 (27.1-33.2)1-334.6 (32.9-36.3)49.1 (47.4-50.8)36.6 (33.9-39.3)35.9 (33.7-38.2).36.5 (35.1-37.9)≥442.5 (39.4-45.7)58.2 (54.0-62.3)45.6 (39.9-51.5)42.8 (38.9-46.7)44.2 (41.7-46.7)  **10-yr CVD risk categories**Low23.7 (21.7-25.8)37.6 (33.5-41.9)28.5 (25.1-32.2)24.8 (22.1-27.8)25.0 (23.3-26.7)High63.0 (56.3-69.2)85.7 (78.9-90.6)61.5 (49.3-72.5)68.6 (59.2-76.7)67.4 (62.7-71.8)**Overall**35.7 (34.3-37.2)49.3 (47.7-50.8)36.6 (34.1-39.2)36.0 (34.3-37.8)37.2 (36.0-38.3)[^9][^10][^11]

[Table 4](#t0020){ref-type="table"} shows the age-adjusted proportion of individuals who were not receiving treatment despite having indication; contrary to the findings of [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, a lower proportion of non-Hispanic blacks were untreated regardless of characteristics. Overall, about half of the people with other races/ethnicities were not receiving treatment, followed by Mexican-Americans, non-Hispanic whites, and non-Hispanic blacks, 49.3% (95% CI: 45.5%--53.0%), 46.5% (95% CI: 42.0%--51.0%), 38.9% (95% CI: 35.3%--42.6%), and 35.1% (95% CI: 32.4%--37.9%), respectively. In all races, younger people, males, people with normal cholesterol, normal HDL, non-diabetic, normal weight, low family income to poverty ratio, and low CVD risk were more likely to remain untreated despite having treatment-indication. For most of the characteristics, despite having indications for treatment, Mexican-Americans and people of other races/ethnicities had a greater proportion of untreated people compared to the other 2 races.Table 4Age-adjusted proportion (with 95% confidence interval) of untreated hypertensive adults among who have antihypertensive treatment indication per characteristics stratified by race, NHANES 2011--16[a](#tf0045){ref-type="table-fn"}.Table 4CharacteristicsNon-Hispanic WhitesNon-Hispanic BlacksMexican-AmericansOther races/ethnicities[b](#tf0050){ref-type="table-fn"}In all races**Age (in years)**20-4448.6 (42.1-55.1)47.9 (41.9-53.9)58.1 (48.7-67.0)65.7 (58.1-72.6)51.9 (47.6-56.2)45-5437.2 (31.2-43.7)28.3 (22.0-35.6)50.0 (39.8-60.2)44.2 (36.5-52.2)37.5 (33.4-41.7)55-6429.1 (24.9-33.6)24.2 (19.7-29.3)30.2 (22.8-38.8)34.1 (28.2-40.5)29.0 (25.9-32.2)≥6527.0 (23.6-30.7)22.1 (19.2-25.2)30.8 (26.5-35.6)29.8 (26.0-33.8)27.0 (24.3-29.8)  **Sex**Male45.9 (41.5-50.2)42.9 (38.0-48.0)56.4 (49.1-63.5)52.9 (47.9-57.7)47.3 (44.4-50.3)Female29.5 (25.0-34.4)28.7 (24.9-32.8)34.8 (27.2-43.2)45.4 (39.4-51.5)32.3 (29.2-35.5)  **Cholesterol level (in mg/dl)**Normal (\<200)41.4 (36.5-46.5)37.8 (33.7-42.0)47.4 (39.1-55.8)56.8 (50.3-63.0)43.2 (39.9-46.6)Borderline (200-239)49.4 (41.2-57.7)49.2 (42.0-56.4)55.5 (43.9-66.6)56.9 (49.9-63.6)50.8 (45.3-56.3)High (≥240)28.2 (24.2-32.7)17.8 (13.0-24.0)39.1 (28.8-50.5)40.1 (30.4-50.5)29.4 (26.0-33.0)  **High-density lipoprotein cholesterol (in mg/dl)**Normal41.3 (36.7-46.0)37.2 (33.6-40.9)51.9 (44.0-59.8)52.7 (47.8-57.7)43.0 (39.9-46.1)Low (\<40 for men & \<50 for women)34.2 (28.7-40.2)28.3 (23.6-33.5)37.8 (30.8-45.4)44.4 (37.9-51.1)35.4 (31.6-39.4)  **Chronic kidney disease**No36.3 (32.3-40.6)33.8 (30.6-37.2)43.6 (37.8-49.7)48.4 (44.2-52.7)38.3 (35.4-41.2)Yes53.7 (46.9-60.3)40.3 (35.9-44.8)51.5 (42.7-60.1)52.9 (43.9-61.6)50.2 (46.5-54.0)  **Diabetes mellitus status**No41.9 (38.2-45.7)40.7 (38.0-43.5)53.7 (46.7-60.6)57.2 (52.9-61.4)44.6 (42.3-47.0)Prediabetes40.3 (30.9-50.5)38.8 (28.6-50.1)53.3 (38.2-67.8)42.4 (30.8-54.9)41.1 (34.7-47.9)Diabetes25.1 (16.0-37.2)17.5 (11.4-25.9)28.5 (19.5-39.8)27.2 (14.5-45.2)24.2 (18.6-30.8)  **Body mass index (in kg/m**^**2**^**)**Normal/underweight (\<25)47.4 (36.7-58.3)55.9 (47.1-64.4)61.4 (40.5-78.8)58.8 (52.2-65.1)51.2 (43.8-58.5)Overweight (25-29.9)42.0 (34.6-49.7)31.4 (24.3-39.5)59.0 (46.5-70.4)54.4 (47.6-61.0)43.9 (39.0-49.0)Obese (≥30)34.9 (31.0-39.1)31.6 (28.2-35.2)39.4 (33.0-46.2)42.7 (36.4-49.2)35.7 (33.1-38.3)  **Family income to poverty ratio**\<241.3 (36.6-46.1)35.9 (30.6-41.6)48.9 (40.3-57.6)51.6 (47.1-56.1)42.3 (39.4-45.3)≥238.0 (33.3-42.9)34.7 (30.5-39.2)43.4 (33.8-53.5)48.5 (42.0-54.9)39.2 (35.7-42.8)  **Number of health care visits within the past year**082.1 (72.8-88.7)85.3 (75.4-91.6)92.4 (84.5-96.4)87.2 (77.4-93.1)87.2 (77.4-93.1)1-338.1 (33.3-43.1)32.6 (29.3-36.0)39.7 (32.0-47.9)47.0 (42.3-51.9)47.0 (42.3-51.9)≥425.2 (20.2-30.8)21.3 (16.1-27.7)25.0 (14.6-39.2)33.9 (26.3-42.5)33.9 (26.3- 42.5)  **10-yr CVD risk categories**Low41.1 (35.4-47.0)34.8 (30.6-39.2)48.3 (41.1-55.5)52.1 (46.4-57.8)42.6 (38.9-46.4)High36.7 (26.2-48.7)25.2 (17.3-35.1)43.8 (28.1-60.8)52.2 (43.0-61.3)37.6 (31.6-43.9)**Overall**38.9 (35.3-42.6)35.1 (32.4-37.9)46.5 (42.0-51.0)49.3 (45.5-53.0)40.4 (38.0-42.8)[^12][^13][^14]

As shown in [Table 5](#t0025){ref-type="table"}, according to race, ordered from the highest age-adjusted proportion, 63.8% (95% CI: 60.0%--67.5%) of non-Hispanic blacks, 60.5% (95% CI: 54.1%--66.5%) of other races/ethnicities, 58.2% (95% CI: 51.7%--64.5%) of Mexican-Americans, and 49.7% (95% CI: 45.0%--54.4%) of non-Hispanic whites were not meeting the treatment goals. Per most of the characteristics, non-Hispanic blacks had higher proportions of people with unmet treatment goals compared to other 3 races. [Figure 2](#f0010){ref-type="fig"} summarizes all four studied prevalence according to race as well as the overall population.Table 5Age-stratified and overall proportion (with 95% confidence interval) of treated hypertensive adults who have unmet treatment goals per characteristics stratified by race, NHANES 2011--16[a](#tf0055){ref-type="table-fn"}.Table 5CharacteristicsNon-Hispanic WhitesNon-Hispanic BlacksMexican-AmericansOther races/ethnicities[b](#tf0060){ref-type="table-fn"}In all races**Age (in years)**20-4445.9 (36.2-55.9)61.6 (54.8-67.9)60.2 (42.5-75.6)62.2 (49.1-73.7)52.2 (45.4-58.9)45-5446.8 (37.6-56.2)64.9 (58.7-70.6)47.9 (30.4-66.0)56.4 (47.7-64.8)51.7 (45.6-57.8)55-6448.6 (42.2-55.1)62.0 (57.4-66.5)57.1 (49.5-64.3)53.8 (44.2-63.2)51.6 (46.9-56.4)≥6561.7 (57.3-66.0)69.5 (65.5-73.2)64.2 (54.1-73.3)66.0 (59.8-71.6)63.1 (59.4-66.5)  **Sex**Male52.8 (45.6-59.8)68.7 (62.3-74.4)66.5 (53.2-77.6)61.8 (52.9-70.0)57.1 (52.0-62.1)Female46.7 (41.5-51.9)61.0 (55.2-66.5)53.3 (44.1-62.3)59.0 (49.8-67.7)51.8 (48.0-55.7)  **Cholesterol level (in mg/dl)**Normal (\<200)50.3 (42.0-58.6)63.0 (55.8-69.7)62.1 (50.4-72.5)64.4 (54.1-73.4)55.3 (49.5-61.0)Borderline (200-239)50.2 (40.2-60.1)75.1 (61.1-85.3)51.6 (38.0-65.0)64.2 (50.3-76.0)55.6 (48.6-62.4)High (≥240)48.0 (40.8-55.1)61.0 (52.7-68.8)57.0 (32.1-78.8)56.4 (42.0-69.9)51.4 (45.7-57.1)  **High-density lipoprotein cholesterol (in mg/dl)**Normal47.9 (42.9-53.0)64.8 (58.7-70.5)59.0 (46.8-70.2)60.6 (49.6-70.7)55.4 (50.8-59.8)Low (\<40 for men & \<50 for women)63.6 (47.9-76.9)61.1 (52.8-68.9)55.8 (46.6-64.6)58.5 (49.1-67.3)51.4 (46.6-56.3)  **Chronic kidney disease**No48.7 (43.6-53.8)61.8 (56.4-66.9)57.6 (50.6-64.3)58.2 (51.3-64.8)52.7 (48.8-56.5)Yes56.9 (42.7-70.1)67.0 (57.0-75.6)59.2 (36.6-78.6)68.0 (53.3-79.8)60.3 (53.0-67.1)  **Diabetes mellitus status**No49.1 (43.6-54.6)62.3 (56.7-67.6)61.3 (51.5-70.2)65.9 (58.3-72.7)53.8 (49.6-58.0)Prediabetes49.1 (34.5-63.8)64.0 (43.9-80.1)71.6 (44.6-88.8)55.3 (40.1-69.6)54.3 (45.1-63.1)Diabetes52.3 (42.0-62.3)68.0 (60.4-74.7)50.0 (31.9-68.2)51.8 (36.3-66.9)55.1 (48.1-62.0)  **Body mass index (in kg/m**^**2**^**)**Normal/underweight (\<25)47.1 (34.6-60.0)64.6 (46.8-79.1)72.2 (63.0-79.8)57.1 (41.1-71.7)52.3 (42.1-62.4)Overweight (25-29.9)49.3 (41.0-57.7)69.6 (60.7-77.3)50.1 (33.9-66.3)66.7 (53.3-77.9)54.6 (47.8-61.3)Obese (≥30)50.2 (44.7-55.7)62.1 (57.5-66.4)57.2 (49.0-65.0)57.0 (50.0-63.7)54.1 (50.4-57.6)  **Family income to poverty ratio**\<246.1 (39.2-53.1)64.3 (57.9-70.3)56.9 (46.5-66.8)58.2 (49.2-66.6)54.4 (50.0-58.8)≥250.3 (44.3-56.3)64.8 (59.8-69.5)56.9 (42.8-69.9)63.1 (53.3-72.0)53.7 (49.1-58.1)  **Number of health care visits within the past year**057.4 (30.8-80.4)84.5 (69.5-92.8)30.4 (20.5-42.4)87.5 (57.8-97.3)60.2 (42.0-76.0)1-349.5 (43.5-55.6)64.5 (59.7-69.1)61.6 (51.6-70.7)58.0 (51.0-64.7)54.8 (50.4-59.1)≥449.2 (41.6-56.8)60.0 (53.5-66.1)54.7 (38.7-69.8)64.2 (53.0-74.1)52.4 (46.9-57.9)  **10-yr CVD risk categories**Low40.4 (33.4-47.7)45.5 (40.2-51.0)45.0 (29.7-61.3)51.6 (43.2-59.9)43.1 (37.8-48.5)High51.5 (41.6-61.3)76.3 (65.6-84.5)65.0 (39.7-84.0)68.2 (50.7-81.8)60.7 (53.9-67.1)**Overall**49.7 (45.0-54.4)63.8 (60.0-67.5)58.2 (51.7-64.5)60.5 (54.1-66.5)54.2 (50.7-57.6)[^15][^16][^17]Fig. 2Age-adjusted proportion of people with hypertension, treatment-eligible for hypertension, untreated among treatment-eligible, and unmet treatment goals among treated according to race, National Health and Nutrition Examination Survey 2011--16.Fig. 2

4. Discussion {#s0030}
=============

This study revealed the racial disparities in age-adjusted prevalence and treatment status of hypertension within the US. Compared to other races, non-Hispanic blacks had higher prevalence and treatment indication for hypertension. Although they were more likely to be treated, about two-thirds were not meeting treatment goals; this proportion was also the highest among all races. The proportion of individuals who could be hypertensive or treatment-eligible for hypertension among races other than the non-Hispanic blacks were similar; however, the proportion of untreated individuals despite being treatment-eligible was substantially higher among Mexican-Americans and other races/ethnicities. To the best of this author\'s knowledge, this is the first epidemiological study to report the racial/ethnic disparities in prevalence, treatment, and control of hypertension among US adults per the 2017 ACC/AHA guideline.

The overall estimates of prevalence and treatment status observed by this study are similar to findings of other studies ([@bb0050]; [@bb0105]; [@bb0115]). Over the past few decades, non-Hispanic blacks had the highest prevalence and unmet treatment goals among all races in the US ([@bb0050]; [@bb0165]). However, the prevalence of hypertension among Africans in Africa are considerably lower than this prevalence. Although genetic similarities exist between Africans in Africa and African-Americans in the US, differences in lifestyles and socioeconomic factors between the African-Americans and Africans in Africa could cause this higher prevalence of hypertension ([@bb0050]; [@bb0065]; [@bb0125]; [@bb0165]). These findings highlight the importance of adopting adequate lifestyle and other preventive measures that could reduce the higher prevalence of hypertension among African-Americans.

The prevalence of overall and uncontrolled hypertension among Mexican-Americans was higher than the prevalence estimates by Muntner and colleagues that also analyzed the NHANES datasets from 2011 to 14 survey years ([@bb0115]); this could be due to age-adjustment. Without age-adjustment, a large proportion of younger people among Mexican-Americans could show a lower prevalence of hypertension among them ([Table 1](#t0005){ref-type="table"}). Dorans et al. reported the age-adjusted prevalence of hypertension according to race following application of the 2017 guideline. The estimates reported by the authors were similar to the estimates of this study ([@bb0050]).

Even though the non-Hispanic blacks were receiving treatment, the treatment was not adequate to reduce the pressure level (i.e., to meet the treatment goals). Regular monitoring of treated individuals is thus essential. This proportion was also substantially higher among people from other races/ethnicities as well as Mexican-Americans. The uncontrolled hypertension could put them at a greater risk of complications as also seen by previous studies ([@bb0115]; [@bb0125]). Even a large proportion of people with high CVD risks had uncontrolled hypertension. Furthermore, the overall age-adjusted proportion of untreated treatment-eligible people was more than 40%, this proportion was higher among other races/ethnicities and Mexican-Americans; the age-adjusted number of health care visits over the past year was also lower among them ([Supplemental Table 2](#ec0010){ref-type="supplementary-material"}). A previous study by Gu et al. suggests that a large proportion of uninsured participants among these races could be responsible for this underutilization of treatment ([@bb0075]). Multiple individual, social, and healthcare-related factors could also cause this underutilization ([@bb0055]; [@bb0075]; [@bb0160]). Ensuring adequate treatment for all these untreated and uncontrolled individuals by overcoming these barriers would be helpful to reduce the complications of hypertension including the disparities associated with treatment.

Despite the dissimilarities, all four age-adjusted proportions were substantially higher among all studied races. To prevent and treat hypertension or its complications, all hypertensive individuals need to adopt lifestyle and other preventive measures such as increasing physical activity or restricting salt intake ([@bb0165]). Additionally, controlling other associated conditions such as diabetes, dyslipidemia, increased body weight, or CKD that increases likelihoods of hypertension would be essential. Some of the conditions such as CVD risk and CKD were disproportionately higher among non-Hispanic blacks compared to other 3 races ([Supplemental Table 2](#ec0010){ref-type="supplementary-material"}), that could cause the difference. Preventing and treating these conditions would be necessary to reduce the racial disparities associated with prevention, treatment, and control of hypertension and its complications including the overall burden. These conditions also share common risk factors; the prevention and control strategies of these conditions are similar to hypertension ([@bb0010]; [@bb0025]; [@bb0060]; [@bb0085]; [@bb0140]).

If any of the participants of the present study (i.e., NHANES 2011--16) ever received an evaluation, were evaluated or treated under previous guidelines such as the JNC 7 guideline ([@bb0035]; [@bb0045]). As those guidelines recommend different cutoffs to define hypertension, treatment indication, and treatment goals, reevaluation of previously treated people is thus important. Despite a substantial increase in prevalence of hypertension following application of the 2017 ACC/AHA guideline, the overall proportion of treatment-eligible people would be similar to previous guidelines ([@bb0115]). Furthermore, people who would be classified as stage 1 hypertensive per the 2017 ACC/AHA guideline, were classified as prehypertensive per the previous guidelines ([@bb0165]). Previous guidelines also recommend preventive measures for prehypertensive individuals ([@bb0035]; [@bb0045]). However, adoption of the new guideline could substantially reduce the complications resulting from hypertension and increase the awareness among all people from early stages of hypertension ([@bb0020]; [@bb0165]; [@bb0170]). Thus, the new guideline has potentials to reduce the racial disparities associated with hypertension and its complications if it is implemented, and adequate preventive and treatment measures are taken ([@bb0115]; [@bb0165]).

Racial disparities in prevalence, treatment, and control of hypertension and other chronic diseases have been studied widely over the past two decades ([@bb0070]; [@bb0075]; [@bb0100]; [@bb0135]). Studies have also shown how the awareness or outcome of diseases differ ([@bb0005]; [@bb0070]; [@bb0075]). Interventions are needed to uptake preventive and treatment measures as well as awareness. Prevention and control programs should incorporate the findings of the present study to reduce these disparities. Strategies such as prescribing (e.g., once-daily regimen if possible), educating (e.g., clearly written instructions), and tracking/encouraging (e.g., encouraging patients to use reminders) have been shown effective to increase medication adherence ([@bb0040]). These strategies require interactions of patients, physicians, and health care delivery systems ([@bb0015]; [@bb0040]). Successful implementation of these strategies is essential to reduce the racial disparities associated with prevention and treatment measures including the overall burden. In addition to races that have poor treatment or control of hypertension, people with the characteristics that were more likely to remain untreated (e.g., younger age and male gender) or uncontrolled (e.g., CKD and high CVD risk) are essential to prioritize.

This study has several notable strengths. First, the estimates were derived from three large nationally representative samples. This survey (i.e., NHANES) used standardized validated methods to obtain BP levels. Using adequate statistical procedures to adjust for sample weights and age along with a large sample size also enabled reporting of prevalence on a wide range of background characteristics ([@bb0090]; [@bb0115]). The limitations of the present study also merit discussion. The NHANES data was cross-sectional, and the BP was measured on a single day; this could cause some overestimation as the 2017 ACC/AHA recommends using measures of multiple days to confirm the diagnosis of hypertension ([@bb0115]; [@bb0165]). Moreover, as earlier studies found a higher proportion of untreated people among Hispanics other than Mexican-Americans, grouping them with non-Hispanic Asians and other races as a separate category (i.e., other races/ethnicities) could lead to some overestimation in that group.

5. Conclusion {#s0035}
=============

This study reported the racial/ethnic disparities associated with prevalence, treatment, and control of hypertension among US adults per the 2017 ACC/AHA guideline. Although the age-adjusted prevalence of hypertension was substantially higher among all races, the non-Hispanic blacks had the highest prevalence regardless of characteristics. Treatment and control disparities also exist where the majority of non-Hispanic blacks were not meeting the treatment goals, and a substantial proportion of Mexican-Americans or people of 'other races/ethnicities' were not receiving treatment despite being eligible for antihypertensive treatment. Interventions are needed to increase prevention, treatment, and control measures by all races to reduce racial disparities associated with hypertension burden, including the complications resulting from it.

The following are the supplementary data related to this article.Supplemental Table 1Definition of outcome variables.Supplemental Table 1Supplemental Table 2Age-stratified proportion of adults with selected characteristics stratified by race, NHANES 2011--16.Supplemental Table 2
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[^1]: Abbreviations: CVD: Cardiovascular disease, DBP: Diastolic blood pressure, NHANES: National Health and Nutrition Examination Survey, SBP: Systolic blood pressure, SE: Standard error.

[^2]: Numbers are presented as weighted percentages and unweighted numbers unless otherwise specified.

[^3]: Numbers may not add up to total because of missing values.

[^4]: Other races/ethnicities include non-Hispanic Asians, other Hispanics, and other races including multi-races.

[^5]: *p*-Values obtained by chi-square tests (for categorical variables) or t-tests (continuous variables).

[^6]: Abbreviations: CVD: Cardiovascular disease, NHANES: National Health and Nutrition Examination Survey.

[^7]: If the systolic/diastolic blood pressure cutoff was ≥130/80 mmHg or a person reported taking antihypertensive medication. This includes both stages 1 and 2 hypertension.

[^8]: Other races/ethnicities include non-Hispanic Asians, other Hispanics, and other races including multi-races.

[^9]: Abbreviations: CVD: Cardiovascular disease, NHANES: National Health and Nutrition Examination Survey.

[^10]: Individuals with stage 2 hypertension, stage 1 hypertension with diabetes, chronic kidney disease or high CVD risk, and systolic blood pressure ≥ 130 mmHg with ≥65 years of age were considered as treatment-eligible for hypertension.

[^11]: Other races/ethnicities include non-Hispanic Asians, other Hispanics, and other races including multi-races.

[^12]: Abbreviations: CVD: Cardiovascular disease, NHANES: National Health and Nutrition Examination Survey.

[^13]: Individuals with stage 2 hypertension, stage 1 hypertension with diabetes, chronic kidney disease or high CVD risk, and systolic blood pressure ≥ 130 mmHg with ≥65 years of age were considered as treatment-eligible for hypertension.

[^14]: Other races/ethnicities include non-Hispanic Asians, other Hispanics, and other races including multi-races.

[^15]: Abbreviations: CVD: Cardiovascular disease, NHANES: National Health and Nutrition Examination Survey.

[^16]: If the systolic/diastolic blood pressure was ≥130/80 mmHg among individuals taking any BP lowering drugs (age groups \<65 years) or the systolic blood pressure was ≥130 mmHg (age groups ≥65 years), then they were considered as persons with unmet treatment goals.

[^17]: Other races/ethnicities include non-Hispanic Asians, other Hispanics, and other races including multi-races.
